1. Home
  2. WAFU vs APRE Comparison

WAFU vs APRE Comparison

Compare WAFU & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WAFU

Wah Fu Education Group Limited

N/A

Current Price

$1.41

Market Cap

5.8M

Sector

Real Estate

ML Signal

N/A

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

N/A

Current Price

$0.52

Market Cap

5.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WAFU
APRE
Founded
1999
2006
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8M
5.7M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
WAFU
APRE
Price
$1.41
$0.52
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $3.30
AVG Volume (30 Days)
24.1K
★ 150.1K
Earning Date
07-31-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.22
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.22
$0.41
52 Week High
$3.06
$1.49

Technical Indicators

Market Signals
Indicator
WAFU
APRE
Relative Strength Index (RSI) 40.98 42.04
Support Level $1.32 $0.41
Resistance Level $1.53 $0.81
Average True Range (ATR) 0.04 0.06
MACD -0.01 0.01
Stochastic Oscillator 15.00 52.63

Price Performance

Historical Comparison
WAFU
APRE

About WAFU Wah Fu Education Group Limited

Wah Fu Education Group Ltd is involved in providing online exam preparation services and related technology solutions, and also produces online training course materials in China. It develops online educational materials that are offered through the cloud and that can be used for a wide range of purposes, such as standard examination preparation, professional training, and interactive programs for educational purposes other than exam preparation. Its segments are Online Education Services and Technological Development and Operation Service. The company generates maximum revenue from the Online Education Services segment.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: